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OBJECTIVES We sought to evaluate the relationship between the angiotensin-converting enzyme (ACE)
genotype and the change in forearm vasoreactivity in response to a three-month course of oral
estrogen in postmenopausal women.
BACKGROUND The ACE genotype is a known predictor of the response to an ACE inhibitor drug; however,
it is not clear whether it can modify the effect of estrogen replacement therapy (ERT) on
endothelial function in postmenopausal women.
METHODS Fifty-five postmenopausal women received 0.625 mg of conjugated equine estrogen daily for
three months. Forearm blood flow (FBF) was measured by strain-gauge plethysmography.
RESULTS Twenty-one, 25 and 9 patients had the insertion/deletion (ID), II and DD genotypes,
respectively. Plasma ACE activity was significantly higher at baseline in patients with either
the DD or ID genotype than in those with the II genotype (p , 0.05). A significant decrease
in plasma ACE activity with ERT was seen in the ID and II genotypes (p , 0.05), but not
in the DD genotype. There were no significant differences in the FBF responses to reactive
hyperemia at baseline between the three groups. Estrogen replacement therapy did not alter
the FBF response to reactive hyperemia in the DD genotype (4.0 6 1.3%), although ERT
significantly increased the FBF response in the ID and II genotypes (32.6 6 7.5% and 30.6 6
6.5%, respectively; p , 0.05). Forearm blood flow after administration of sublingual
nitroglycerin did not change over three months in any of the three groups.
CONCLUSIONS These findings suggest that the effect of ERT in postmenopausal women on forearm
endothelial function may be determined in part by the genotype of the ACE gene. (J Am
Coll Cardiol 2001;37:1529–35) © 2001 by the American College of Cardiology
Premenopausal women have a lower risk of coronary heart
disease than men, but the risk rapidly rises in women after
menopause (1). Estrogen replacement therapy (ERT) in
postmenopausal women has been associated with a reduc-
tion in cardiovascular events in some but not all studies
(2–5). Estrogen exerts many protective effects on the car-
diovascular system, including a lipid-lowering effect (6), an
antioxidant effect (7), inhibition of fibrosis (8) and a
vasodilating effect (9,10). Some studies have shown that the
short- and long-term administration of estrogen increases
forearm reactive hyperemia in postmenopausal women (9–
12). Reactive hyperemia in the peripheral arteries is medi-
ated by endothelial-derived nitric oxide (NO) (13).
Through its alpha-type receptor, estrogen may directly
upregulate endothelial nitric oxide synthase (eNOS) gene
expression (14,15). The lipid-lowering and anti-oxidant
effects of estrogen may also improve endothelial-vascular
function overall and diminish vascular disease, thereby
increasing vascular NO production (16,17). However, the
mechanism by which estrogen improves endothelial func-
tion is thought to be complex and multifactorial.
The renin-angiotensin system is reportedly suppressed by
hormone therapy in postmenopausal women, with no in-
crease in blood pressure (18,19). A decline in angiotensin-
converting enzyme (ACE) activity may be one of the factors
that protect against cardiovascular disease. The ACE inhib-
itors have been shown, in some clinical studies, to improve
endothelial function (20,21). In addition, ACE inhibition
induces the accumulation of bradykinin through the inhi-
bition of kininase II. Bradykinin causes NO to be released
from endothelial cells (22,23).
An insertion/deletion (ID) polymorphism of the ACE
gene, which has been mapped to human chromosome
17q23, has been reported to be involved in various cardio-
vascular diseases, such as myocardial infarction (24), left
ventricular remodeling after myocardial infarction (25) and
complications of diabetes (26). Some studies (27,28) have
suggested that the endothelial effects of ACE inhibitors
differ according to this gene’s polymorphism.
However, it is not clear whether the ACE genotype can
modify the response to ERT on endothelial function in
postmenopausal women. The present study determined the
relationship between the ACE genotype and the change in
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forearm vasoreactivity over a three-month course of oral
ERT in postmenopausal women.
METHODS
Subjects. A total of 55 postmenopausal Japanese women
(age 48 to 57 years) were enrolled in the study. Each subject
had experienced natural menopause for at least one year, but
not longer than five years. Each woman was of normal
weight, with a body mass index #25 kg/m2. Menopausal
status was confirmed by a serum follicle-stimulating hor-
mone concentration .40 mIU/ml and a serum estradiol
concentration ,20 pg/ml. Excluded from the study were
patients with hypertension, diabetes, a cigarette smoking
habit, clinical manifestations of atherosclerosis (e.g., coro-
nary artery disease, peripheral artery disease, cerebrovascular
disease), venous thromboembolism, liver disorders, unex-
plained vaginal bleeding and a personal or family history of
breast cancer. Before being enrolled in the study, each
subject underwent a physical examination, including a
gynecologic evaluation and mammography. None had re-
ceived ERT, other steroid hormones or any medication
known to affect blood pressure or lipoprotein metabolism.
Protocol. All subjects received conjugated equine estrogen
(Premarin; Wyeth-Ayerst Laboratories, Philadelphia,
Pennsylvania), 0.625 mg daily each morning for three
months. All participants were followed for three months.
Each subject was requested to avoid making any changes in
lifestyle or dietary habits during the study. The Ethics
Committee of the Department of Obstetrics and Gynecol-
ogy of Hiroshima University approved the study protocol.
Written, informed consent for participation was obtained
from each subject.
The vasodilator response to reactive hyperemia, an index
of endothelium-dependent vasodilation, and to sublingual
administration of nitroglycerin, an index of endothelium-
independent vasodilation, was evaluated in each subject at
baseline and again after three months. This evaluation
began at 8:30 AM. Each subject had fasted the previous night
for at least 12 h. Before fasting, they rested in the supine
position in a quiet, air-conditioned room (constant temper-
ature 22 to 25°C). After the subject had rested for 30 min in
that position, the basal forearm blood flow (FBF) was
measured as described subsequently. Next, the effects of
reactive hyperemia and sublingual administration of nitro-
glycerin on FBF were evaluated by inflating a cuff over the
left upper arm to 280 mm Hg for 5 min. After the cuff
occlusion was released, FBF was measured for 3 min. Next,
a nitroglycerin tablet (0.3 mg) (Nihonkayaku Co., Tokyo,
Japan) was administered sublingually, and FBF was again
measured for 3 min. In the preliminary study, we confirmed
the reproducibility of the FBF responses to reactive hyper-
emia and sublingual NTG on two separate occasions in 28
healthy men (mean age 27 6 5 years). The coefficients of
variation were 4.3% and 2.8%, respectively.
The baseline fasting serum concentrations of total cho-
lesterol, high density lipoprotein (HDL) cholesterol, trig-
lycerides, creatinine, glucose, electrolytes, nitrite/nitrate and
ACE activity were obtained after a 30-min period of rest.
The body weight, blood pressure and heart rate were
determined at baseline and again after three months of
treatment.
Measurement of FBF. Forearm blood flow was measured
with a mercury-filled Silastic strain-gauge plethysmograph
(EC-5R, D. E. Hokanson, Inc., Issaquah, Washington), as
previously described (29,30). The intra-observer coefficient
of variation was 3.0 6 1.6%. Four plethysmographic mea-
surements were averaged to obtain FBF at baseline, during
reactive hyperemia and after the administration of sublin-
gual nitroglycerin.
Deoxyribonucleic acid studies. Genomic deoxyribonu-
cleic acid (DNA) was isolated from peripheral leukocytes.
The genotype of the ACE gene was determined by the
polymerase chain reaction (PCR), according to the method
of Rigat et al. (31). The PCR analysis was performed with
50 ml of the reaction solution containing 50 pmol/liter of
each primer, 1.5 mmol/liter of MgCl2, 50 mmol/liter of
KCl, 10 mmol/liter of tris-HCl (pH 8.3), 200 mmol/liter of
each deoxynucleoside triphosphate and 2.5 U of Taq DNA
polymerase (Takara Shuzo Co., Kyoto, Japan).
Analytical methods. Samples of venous blood were placed
in polystyrene tubes containing sodium EDTA (1 mg/ml).
The EDTA-containing tubes were immediately chilled in
an ice bath. Next, the plasma was separated by centrifuga-
tion at 3,100 rpm at 4°C for 10 min. Serum was separated
at 1,000 rpm at room temperature for 10 min. Samples were
stored at 280°C until assayed. Routine chemical methods
were used to determine the serum concentrations of total
cholesterol, HDL cholesterol, triglycerides, creatinine, glu-
cose and electrolytes. The serum concentration of low
density lipoprotein (LDL) cholesterol was determined by
Freidewald’s method (32). Serum concentrations of follicle-
stimulating hormone and estradiol were analyzed by using a
commercially available radioimmunoassay kit (Boehringer,
Mannheim, Germany).
Nitrite/nitrate concentrations were measured with an
auto-analyzer (flow injection analyzer, TCI-NOX1000,
Tokyo Kasei Kogyo, Tokyo, Japan), which uses a protocol
based on the Griess reaction (33).
The ACE activity (IU/liter at 37°C) was measured with
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
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ACE color (Fujirebio Co., Ltd., Tokyo, Japan). Plasma
renin activity was measured by a radioimmunoassay kit.
Statistical analysis. The results are presented as the mean
value 6 SE. One-way analysis of variance (ANOVA) was
used to compare the baseline clinical characteristics of the
three ACE genotypes. The comparison of the time-course
curves of FBF during reactive hyperemia at baseline be-
tween the three ACE genotypes was done by using two-way
ANOVA for repeated measures on one factor, followed by
the Bonferroni correction for multiple, paired comparisons.
The repeated factor was time of reactive hyperemia, and the
nonrepeated factor was one group versus the other group
(Fig. 1). Comparisons between the treatment groups, with
respect to changes in variables, were performed with ad-
justed mean values by analysis of co-variance, using the
baseline data as covariates. Comparisons of variables, in-
cluding maximal FBF response to nitroglycerin (Fig. 2),
were carried out by one-way ANOVA, followed by the
Bonferroni correction. Percent changes of the maximal FBF
response to reactive hyperemia were compared between the
three ACE genotypes by using one-way ANOVA (Fig. 3).
A level of p , 0.05 was accepted as statistically significant.
Data were processed using the Software package Statview
IV (Brainpower) or Super ANOVA (Abacus Concepts,
Berkeley, California).
RESULTS
Effects of ERT on baseline clinical variables. The ACE
genotype distribution and clinical variables of the 55 post-
menopausal women at baseline and again after three months
are summarized in Table 1. Among the 55 patients, 9, 21
and 25 had the DD, ID and II genotypes, respectively. Age,
body weight, years since menopause, blood pressure, heart
rate and lipid profile were similar between the three groups.
Twelve weeks of ERT significantly reduced the serum
Figure 1. Forearm blood flow at rest and during reactive hyperemia in the DD (n 5 9), ID (n 5 21) and II (n 5 25) angiotensin converting enzyne genotype
groups at baseline. There was no significant difference in reactive hyperemia between the three groups at baseline.
Figure 2. Maximal forearm blood flow (FBF) after sublingual administration of nitroglycerin in the DD (n 5 9), ID (n 5 21) and II (n 5 25) ACE
genotype groups at baseline and after three months of estrogen replacement therapy (ERT). Changes in FBF similar to those seen before and after ERT
were observed in the three groups after the administration of sublingual nitroglycerin. Results are presented as the mean value 6 SE. N.S. 5 not significant.
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concentrations of total cholesterol and LDL cholesterol
(p , 0.05) and increased the concentration of HDL
cholesterol (p , 0.05), as compared with the baseline values,
in all three ACE genotype groups. These changes were
similar in the three groups. The baseline serum estradiol
concentration in the three groups remained within the
menopausal range. The serum estradiol concentration after
three months of ERT was significantly higher than that at
baseline (p , 0.01) in the three groups. The body weight,
blood pressure and heart rate remained unchanged in the
three groups at three months. No abnormal endometrial
histologic findings (e.g., hyperplasia or carcinoma) were
noted during the study.
Effects of ERT on ACE activity or nitrite/nitrate con-
centration and ACE genotype. The plasma ACE activity
was significantly higher in the patients with either the DD
or ID genotype than in those with the II genotype (p ,
0.05). A significant decrease in plasma ACE activity with
ERT was seen in the ID and II genotypes (ID: from 13.9 6
1.0 to 12.2 6 0.9 IU/liter at 37°C, p , 0.01; II: from 11.0 6
0.4 to 9.8 6 0.6 IU/liter at 37°C, p , 0.01), but not in the
DD genotype (from 15.0 6 0.9 to 14.4 6 1.0 IU/liter at
37°C). The serum nitrite/nitrate concentrations were similar
in the three groups at baseline. A significant increase in the
nitrite/nitrate concentration with ERT was also seen in the
ID and II genotypes (ID: from 29.3 6 2.3 to 39.2 6 4.1
mmol/liter, p , 0.05; ID: from 28.2 6 3.7 to 36.1 6 4.6
mmol/liter, p , 0.05), but not in the DD genotype (from
26.0 6 2.0 to 30.3 6 3.6 mmol/liter) (Table 1).
Effect of ERT on endothelial function and ACE geno-
type. There were no significant differences in the FBF
responses to reactive hyperemia between the three groups at
baseline (Fig. 1). The changes in FBF after sublingual
administration of nitroglycerin were similar between the
three groups at baseline versus after the three-month period
of observation (Fig. 2). In response to ERT, there was no
increase in the FBF responses to reactive hyperemia noted
in the DD genotype group. A significant increase in the
FBF responses to reactive hyperemia after ERT was re-
stricted to those with the ID (mean percent change 32.6 6
7.5%, p , 0.05) and II genotypes (mean percent change
30.6 6 6.5%, p , 0.05). The FBF increases in the ID and
II genotype groups were significantly different from that in
the DD genotype group (Fig. 3).
DISCUSSION
In the present study, we evaluated the relationship between
the ACE genotype and the change in the forearm vasodi-
lator response to ERT in postmenopausal women. We
found that the change in reactive hyperemia of the forearm
peripheral vessels after three months of oral estrogen ther-
apy appeared to be related to the ACE genotype.
Estrogen and endothelial function. Previous studies have
shown that the transdermal and oral administration of
estrogen improves forearm endothelial function in post-
menopausal women (9–12). This is one of the major
benefits of estrogen in the prevention of coronary heart
disease.
Figure 3. Absolute changes in percent maximal forearm blood flow (FBF)
during reactive hyperemia after three months of estrogen replacement
therapy, according to the ACE genotype. A significant increase in the
maximal FBF during reactive hyperemia was seen only in the ID and II
genotype groups (*p , 0.05). The results are presented as the mean value 6
SE.
Table 1. Clinical Variables in Each Genotype Group at Baseline and After Three Months of Estrogen Replacement Therapy
Variable
DD (n 5 9) ID (n 5 21) II (n 5 25)
Baseline 3 Months Baseline 3 Months Baseline 3 Months
Body weight (kg) 52.5 6 2.6 52.7 6 2.4 54.2 6 1.8 54.8 6 1.9 53.5 6 1.6 54.1 6 1.9
Body mass index (kg/m2) 22.1 6 0.8 22.2 6 0.6 23.2 6 0.5 23.5 6 0.7 22.3 6 0.6 22.6 6 0.5
Systolic blood pressure (mm Hg) 132.7 6 7.7 129.4 6 7.4 128.0 6 3.7 124.5 6 3.1 130.0 6 4.1 129.3 6 4.1
Diastolic blood pressure (mm Hg) 82.0 6 3.7 79.0 6 4.4 77.8 6 2.8 75.5 6 2.6 80.5 6 4.2 78.6 6 2.6
Heart rate (beats/min) 62.7 6 2.2 61.1 6 1.1 65.9 6 1.9 66.0 6 1.9 66.7 6 2.2 66.9 6 2.2
Total cholesterol (mg/dl) 237.3 6 15.7 208.2 6 12.5* 240.9 6 8.8 221.1 6 8.9* 230.0 6 9.2 213.2 6 8.0*
Triglycerides (mg/dl) 118.6 6 109 127.1 6 7.4 120.1 6 14.7 126.4 6 12.2 117.5 6 22.2 136.6 6 18.3
HDL cholesterol (mg/dl) 70.7 6 3.3 75.9 6 3.7* 72.3 6 3.3 76.7 6 3.4* 71.8 6 3.4 78.8 6 4.3*
LDL cholesterol (mg/dl) 158.0 6 19.3 125.1 6 15.6* 154.7 6 9.7 136.1 6 9.8* 145.8 6 7.6 123.8 6 7.3*
Estradiol (pg/ml) 12.8 6 2.1 42.6 6 2.2* 12.6 6 1.0 36.5 6 6.3* 14.5 6 1.9 46.4 6 8.3*
Plasma ACE activity (IU/liter at 37°C) 15.0 6 0.9† 14.4 6 1.2 13.9 6 1.0† 12.2 6 0.9* 11.0 6 0.4 9.8 6 0.6*
Nitrite/nitrate (mmol/liter) 26.0 6 2.0 30.3 6 3.6 29.3 6 2.3 39.2 6 4.1* 28.2 6 3.7 36.1 6 4.6*
Basal FBF (ml/min per 100 ml tissue) 6.2 6 0.5 6.2 6 0.8 5.8 6 0.3 5.9 6 0.4 6.2 6 0.4 6.1 6 0.5
*p , 0.05 versus baseline (month 0). †p , 0.05 versus genotype II group. Results are presented as the mean value 6 SE.
ACE 5 angiotensin-converting enzyme; FBF 5 forearm blood flow; HDL 5 high density lipoprotein; LDL 5 low density lipoprotein.
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Estrogen may block the release of endothelium-derived
constricting factors (34) or may enhance the release or
bio-availability of NO from endothelial cells, resulting in
increased cyclic guanosine monophosphate in the underly-
ing smooth muscle and vasorelaxation (35,36). Through its
alpha-type receptor, estrogen may directly upregulate eNOS
gene expression (14,15). Another possibility is that
estrogen-induced changes in lipoprotein levels indirectly
result in increased production of NO. For instance,
estrogen-induced reductions in LDL and oxidized LDL
and increases in HDL should improve endothelial-vascular
function overall and diminish vascular disease, thereby
increasing vascular NO production (16,17). The mechanism
by which estrogen improves endothelial function is thought
to be complex and multifactorial.
ACE activity and endothelial function. The renin-
angiotensin system has been reported to be suppressed by
hormone replacement therapy in hypertensive menopausal
women, without an increase in blood pressure, as well as in
normotensive postmenopausal women (18,19). Elevated
ACE activity might lead to high angiotensin II levels, which
might then contribute to increased cardiovascular risk. The
ACE inhibitors have been shown, in some clinical studies,
to improve endothelial function (20,21). Because ACE is
identical to kininase II and is present on the vascular
endothelium, bradykinin is inactivated by ACE. Thus, it is
assumed that ACE inhibitors may act on kininase II and
increase the tissue concentration of bradykinin, which, in
turn, augments the vasodilation induced by bradykinin,
leading to an increase in NO synthesis (22,23).
Polymorphisms of the ACE gene have been found, and
the presence of the deletion (D) allele has been associated
with higher concentrations of circulating and tissue ACE
(37). The DD genotype has also been associated with an
increased risk of coronary restenosis and myocardial infarc-
tion in some, but not all, studies. In our present study, the
plasma ACE activity correlated with the ACE genotype in
Japanese normotensive postmenopausal women. The
plasma ACE activity in subjects with the DD genotype was
not significantly higher than that in subjects with the ID
genotype in our study group, which is consistent with the
findings in another hypertensive Japanese group (38).
ACE genotype and vasodilation to estrogen. The pur-
pose of the present study was to determine whether the
ACE genotype affects the vasoactive response to ERT in
postmenopausal women. Some studies have suggested a
relationship between the genotype and the physiologic
effects of ACE inhibition, with an attenuation of the
beneficial effect noted with the D allele (27,28). In the
present study, we found no difference in the baseline FBF
responses to reactive hyperemia between the different geno-
types, as found in some studies (28,39). However, the
increase in the FBF responses to reactive hyperemia with
three months of oral estrogen therapy was restricted to
subjects with the ID and II genotypes. Although the reason
for this observation is not explained by this study, some
possibilities might be considered. It is well known that a
balance between angiotensin II and NO is important in the
regulation of vascular tone (40). Angiotensin II increases
vascular superoxide production through the activation of
membrane-associated nicotinamide adenine dinucleotide
diaphorase/nicotinamide adenine dinucleotide phosphate
diaphorase oxidase, resulting in NO inactivation and toxic
peroxynitrite production (40). Therefore, ACE inhibitors
may increase NO by inhibiting angiotensin II production.
Furthermore, under physiologic conditions, endogenous
bradykinin is limited by ACE. Bradykinin binds to B2
receptors on the endothelial cell surface, causing the release
of NO (41). The ACE inhibitors prevent bradykinin deg-
radation, leading to increases in NO release. Anderson et al.
(28) reported that the percent reduction of ACE activity
was greater in those with the II genotype than in those with
the DD genotype after the administration of the ACE
inhibitor enalapril. In the present study, a significant de-
crease in plasma ACE activity and an increase in the serum
concentration of nitrite/nitrate with ERT were seen in
subjects with the ID and II genotypes, but not in those with
the DD genotype. This finding suggests that the increase in
FBF responses to reactive hyperemia after ERT is related to
the degree of inhibition of the plasma ACE concentration.
Indeed, we found no significant differences in the changes of
other variables, such as HDL cholesterol, LDL cholesterol
or body weight, after ERT between the three groups.
Furthermore, it may be related to the increased tissue level
of ACE, an attenuated interaction with estrogen and the
tissue ACE or increased levels of oxidative stress in subjects
with the DD genotype. In addition, downregulation of the
angiotensin II type receptor in those with the DD genotype
has also been recently suggested (42). The duration of the
treatment may also be related to the genotype, thus affecting
the results (43).
The present study demonstrated that a polymorphism of
the ACE gene is a useful predictor of the effect of ERT on
forearm reactive hyperemia in postmenopausal women. We
believe that this is an instance in which an association
between the vasoactive response to ERT in post-
menopausal women and ACE genotype has been demon-
strated.
Study limitations. A superior method to assess the endo-
thelium may be the direct intra-arterial infusion of a
vasoactive agent in the forearm. Recently, Celermajer et al.
(44) developed a noninvasive method for producing reactive
hyperemia to assess endothelial function. In the present
study, we measured the FBF response to reactive hyperemia
using strain-gauge plethysmography. This technique is use-
ful for assessing forearm arterial resistance and endothelial
function. This technique was simple and reproducible and
caused no adverse effects. We recommend this noninvasive
technique to assess endothelial function in routine clinical
examinations and in future studies.
Several limitations should be considered in assessing this
study. First, this was not a double-blind, placebo-controlled
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clinical study. Second, subjects were not matched. Also,
there were relatively few participants, especially those with
the DD genotype, as compared with large epidemiologic
trials. However, significant differences in the FBF response
to reactive hyperemia after ERT and the plasma concentra-
tions of ACE were observed in the DD genotype group. A
more significant difference in these variables might be found
in a similar study with a larger sample size.
Conclusions. The present study suggests that the effect of
ERT on forearm reactive hyperemia may be determined in
part by the ACE genotype in postmenopausal women.
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